

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TDM2/18 - Therapeutic Drugs

Dead line: 12.10.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability						Traceability																		
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}				
Set of samples 1																										
(81) Digoxin					10																					
Samples and groups		[nmol/L]																								
Sample A1		1,58	0,36	23	10									0		CRV	1,583	0,016	36%	1,01	2,16	10	10	100%		
(4) LIA, ILMA		1,48	0,41	27	7	0																		7		
Other					3	0																			3	
																1x 2, 2x 6										
Sample B1		2,70	0,42	15	10									0		CRV	2,688	0,027	36%	1,72	3,66	10	10	100%		
(4) LIA, ILMA		2,66	0,60	23	7	0																			7	
Other					3	0																			3	
																1x 2, 2x 6										
(82) Theophylline					3																					
Samples and groups		[µmol/L]																								
Sample A1		35,5	1,2	3,5	3									0		CRV	37,2	0,37	24%	28,2	46,2	3	3	100%		
Other					3	0																			3	
																1x 2, 1x 4, 1x 6										
Sample B1		73,7	2,6	3,5	3									0		CRV	75,6	0,75	24%	57,4	93,8	3	3	100%		
Other					3	0																			3	
																1x 2, 1x 4, 1x 6										
(84) Phenobarbital					4									4	4	100%										0
Samples and groups		[µmol/L]																								
Sample A1		48,9	6,7	14	4		CVP	47,8	1,9	20%	38,2	57,4	4	4	100%										0	
Other					4	0							4	4	100%											4
							1x 2, 2x 4, 1x 6																			
Sample B1		136	11	8,2	4		CVP	128	4,0	20%	102	154	4	4	100%										0	
Other					4	0							4	4	100%											4
							1x 2, 2x 4, 1x 6																			
(85) Phenytoin					3									3	3	100%										0
Samples and groups		[µmol/L]																								
Sample A1		79,3	5,3	6,7	3		CVP	75,8	1,8	20%	60,6	91	3	3	100%										0	
Other					3	0							3	3	100%											3
							1x 4, 2x 6																			
Sample B1		13,1	1,2	8,8	3		CVP	12,2	0,42	20%	9,76	14,7	3	3	100%										0	
Other					3	0							3	3	100%											3
							1x 4, 2x 6																			
(86) Carbamazepin					8									8	7	88%										0
Samples and groups		[µmol/L]																								
Sample A1		35,9	5,7	16	8		CVP	33,9	0,68	20%	27,1	40,7	8	8	100%										0	
Other					8	0							8	8	100%											8
							3x 2, 3x 4, 2x 6																			
Sample B1		32,4	4,3	13	8		CVP	31,6	0,72	20%	25,2	38	8	7	88%										0	

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TDM2/18 - Therapeutic Drugs

Dead line: 12.10.2018

Test	[unit]						Comparability						Traceability										
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(86) Carbamazepin					8						8	7	88%							0			
Samples and groups	[µmol/L]																						
Sample B1		32,4	4,3	13	8	CVP	31,6	0,72	20%	25,2	38	8	7	88%						0			
Other					8	0						8											
							3x 2, 3x 4, 2x 6																
(88) Valproic acid					8						8	8	100%							0			
Samples and groups	[µmol/L]																						
Sample A1		255	23	9,2	8	CVP	249	5,2	20%	199	299	8	8	100%						0			
Other					8	0						8											
							3x 2, 3x 4, 2x 6																
Sample B1		403	18	4,4	8	CVP	388	7,1	20%	310	466	8	8	100%						0			
Other					8	0						8											
							3x 2, 3x 4, 2x 6																
Set of samples 2																							
(89) Amicacin					2						2	2	100%							0			
Samples and groups	[µmol/L]																						
Sample A2		11,5	0,17	1,4	2	CVP	10,3	0,40	20%	8,24	12,4	2	2	100%						0			
Other					2	0						2											
							2x 2																
Sample B2		29,3	1,3	4,4	2	CVP	29,6	0,55	20%	23,6	35,6	2	2	100%						0			
Other					2	0						2											
							2x 2																
(90) Gentamicin					5						5	4	80%							0			
Samples and groups	[µmol/L]																						
Sample A2		22,3	2,3	10	5	CVP	21,7	1,4	31%	14,9	28,5	5	4	80%						0			
Other					5	0						5											
							1x 1, 2x 2, 2x 4																
Sample B2		16,1	1,8	11	5	CVP	17,5	1,0	31%	12	23	5	5	100%						0			
Other					5	0						5											
							1x 1, 2x 2, 2x 4																
(92) Vancomycin					8						8	7	88%							0			
Samples and groups	[µmol/L]																						
Sample A2		20,8	5,4	26	8	CVP	21,1	0,95	28%	15,1	27,1	8	7	88%						0			
Other					8	0						8											
							1x 1, 2x 2, 3x 4, 1x 6, 1x 99																
Sample B2		9,21	1,8	19	8	CVP	9,38	0,32	28%	6,75	12,1	8	7	88%						0			
Other					8	0						8											
							1x 1, 2x 2, 3x 4, 1x 6, 1x 99																
(93) Methotrexate					2						2	1	50%							0			
Samples and groups	[µmol/L]																						
Sample A2		4,43	1,8	40	2	CVP	4,86	0,39	30%	3,4	6,32	2	1	50%						0			
Other					2	0						2											
							1x 2, 1x 4																
Sample B2		2,67	1,0	39	2	CVP	3,11	0,30	30%	2,17	4,05	2	1	50%						0			
Other					2	0						2											
							1x 2, 1x 4																